Pregnancy-relevant infections

Clinical information

The term TORCH encompasses all infectious agents that can be transferred from mother to child in the uterus, during birth or after birth via vertical infection. These include Toxoplasma gondii, rubella virus, cytomegalovirus (CMV), herpes simplex virus (HSV) and other pathogens such as Chlamydia trachomatis, parvovirus B19, Treponema pallidum and varicella zoster virus (VZV). Primary infections during pregnancy are especially feared, since they are associated with an increased risk of damage to the child.

Diagnostics

The determination of antibodies against TORCH parameters is an essential part of pre-, peri- and postnatal care. The tests allow the immune status of the mother to be established and the risks to an existing pregnancy assessed. TORCH tests are generally performed during the first trimester of pregnancy. Newborns can also be tested if an infection is suspected. The initial investigation of antibodies against TORCH pathogens is aimed at determining the immune status of the mother to enable differentiation between acute primary and past infections or reactivations during the course of pregnancy. If diagnosed early, some TORCH infections can be treated effectively, reducing the risk of birth defects or loss of the foetus.

Methods

ChLIA (31)

ELISA (35)

EUROLINE (8)

IIFT (12)

PCR (1)

WESTERNBLOT (7)

Technology	Parameter	Substrate	Species	Calibration	Ig Class	Format	Order No.
IIFT	Zika virus (ZIKV)	infected and non- infected cells (2 BIOCHIPs per field)	EU 14		IgG IgM IgG IgM	10 x 05 10 x 05 10 x 10 10 x 10	FI 2668-1005 G FI 2668-1005 M FI 2668-1010 G FI 2668-1010 M
IIFT	Arbovirus Fever Mosaic 2 Zika virus (ZIKV) Chikungunya virus (CHIKV) Dengue virus types 1 - 4 (DENV)	6 BIOCHIPs per field: infected cells infected cells infected cells	EU 14 EU 14 EU 14		IgG IgM IgG IgM	10 x 05 10 x 05 10 x 10 10 x 10	FI 2668-1005-1 G FI 2668-1005-1 M FI 2668-1010-1 G FI 2668-1010-1 M
IIFT	Arbovirus Profile 3 upper row : Zika virus (ZIKV) Chikungunya virus (CHIKV) Dengue virus types 1 - 4 (DENV) bottom row: TBE virus (TBEV) West Nile virus (WNV) Japanese encephalitis virus (JEV) Yellow fever virus (YFV)	infected cells infected cells infected cells infected cells infected cells infected cells infected cells	EU 14 EU 14 EU 14 EU 14 EU 14 EU 14 EU 14		IgG IgM	10 x 05 10 x 05	FI 2668-1005-3 G FI 2668-1005-3 M
IIFT	Zika virus (ZIKV) EUROPattern	infected and non- infected cells (2 BIOCHIPs per field)	EU 14		IgG PI IgM PI IgG PI IgM PI	10 x 05 10 x 05 10 x 10 10 x 10	FR 2668-1005 G FR 2668-1005 M FR 2668-1010 G FR 2668-1010 M
IIFT	Arbovirus Fever Mosaic 2 EUROPattern Zika virus (ZIKV) Chikungunya virus (CHIKV) Dengue virus types 1 - 4 (DENV)	6 BIOCHIPs per field: infected cells infected cells infected cells	EU 14 EU 14 EU 14		IgG PI IgM PI IgG PI IgM PI	10 x 05 10 x 05 10 x 10 10 x 10	FR 2668-1005-1 G FR 2668-1005-1 M FR 2668-1010-1 G FR 2668-1010-1 M
ELISA	Anti-Zika Virus ELISA (IgG)	antigen-coated microplate wells	recombinant NS1 antigen from Zika virus	2/20/200 RU/ml	IgG	96 x 01	EI 2668-9601 G
ELISA	Anti-Zika Virus ELISA (IgM)	antigen-coated microplate wells	recombinant NS1 antigen from Zika virus	semi-quantitative	IgM	96 x 01	EI 2668-9601 M
ELISA	Anti-Zika Virus ELISA (IgAM)	antigen-coated microplate wells	specific NS1 antigen from Zika virus	semi-quantitative	IgAM	96 x 01	EI 2668-9601 Q
ELISA	Anti-CMV ELISA (IgG) cytomegalovirus	antigen-coated microplate wells	native antigens from CMV	2/20/200 RU/ml	IgG	96 x 01	EI 2570-9601 G
ELISA	Anti-CMV ELISA (IgM) cytomegalovirus	antigen-coated microplate wells	native antigens from CMV	semi-quantitative	IgM	96 x 01	EI 2570-9601 M
ELISA	Avidity: Anti-CMV ELISA (IgG) cytomegalovirus avidity determination	antigen-coated microplate wells	native antigens from CMV	2/20/200 RU/ml	IgG	96 x 01	EI 2570-9601-1 G
ELISA	Anti-CMV p52 ELISA (IgM) cytomegalovirus p52 antigen from CMV	antigen-coated microplate wells	native antigens from CMV	semi-quantitative	IgM	96 x 01	EI 2570-9601-2 M
ELISA	Anti-CMV gB ELISA (IgG) cytomegalovirus glycoprotein B glycoprotein B antigen from CMV	antigen-coated microplate wells	recombinant glycoprotein B antigen from CMV	2/20/200 RU/ml	IgG	96 x 01	EI 2570-9601-3 G
EUROLINE	positive control serum: IgG, human, 50x concentrated for CMV				IgG	05 x 07	CL 2570-0507 G
EUROLINE	positive control serum: IgM, human, 50x concentrated for CMV				IgM	05 x 07	CL 2570-0507 M
EUROLINE	EUROLINE Anti-CMV (IgG)	EUROLINE			IgG IgG IgG	16 x 01 50 x 01 64 x 01	DN 2570-1601-2 G DN 2570-5001-2 G DN 2570-6401-2 G
EUROLINE	EUROLINE Anti-CMV (IgM)	EUROLINE			IgM IgM IgM	16 x 01 50 x 01 64 x 01	DN 2570-1601-2 M DN 2570-5001-2 M DN 2570-6401-2 M
ChLIA	IDS CMV IgG	antigenic coated magnetic particles	CMV antigen	qualitative		100 x 01	IS-ID5401¹
ChLIA	IDS CMV IgM	antigenic coated magnetic particles	CMV antigen	qualitative		100 x 01	IS-ID5402¹
ChLIA	IDS CMV Control Set	3 x 1.5 ml Control 1/2	human serum			2 concentrations	IS-ID5430¹
ChLIA	IDS CMV IgG Avidity	antigenic coated magnetic particles	CMV antigen	qualitative		50 x 01	IS-ID5501¹
ChLIA	IDS CMV Avidity Control Set	3 x 1.0 ml Control 1/2	human serum			2 concentrations	IS-ID5530¹
ELISA	Anti-HSV-1/2 Pool ELISA (IgG) herpes simplex virus native antigens from HSV-1 and HSV-2	antigen-coated microplate wells	native antigens from HSV-1 and HSV-2	2/20/200 RU/ml	IgG	96 x 01	EI 2531-9601-1 G
ELISA	Anti-HSV-1/2 Pool ELISA (IgM) herpes simplex virus native antigens from HSV-1 and HSV-2	antigen-coated microplate wells	native antigens from HSV-1 and HSV-2	semi-quantitative	IgM	96 x 01	EI 2531-9601-1 M
ELISA	Anti-HSV-1 (gC1) ELISA (IgG) herpes simplex virus 1 recombinant glycoprotein C1 from HSV-1	antigen-coated microplate wells	recombinant glycoprotein C1	2/20/200 RU/ml	IgG	96 x 01	EI 2531-9601-2 G
ELISA	Anti-HSV-2 (gG2) ELISA (IgG) herpes simplex virus 2 recombinant glycoprotein G2 from HSV-2	antigen-coated microplate wells	recombinant glycoprotein G2	2/20/200 RU/ml	IgG	96 x 01	EI 2532-9601-2 G
WESTERNBLOT	antibodies against Herpes simplex virus (HSV) IgG positive control				IgG	50 x 05	CW 2531-5005 G
WESTERNBLOT	Anti-HSV-1 / HSV-2 gG-2 EUROLINE-WB (IgG) Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2	Westernblot	whole antigen, SDS extract of HSV-1 plus purified gG2		IgG	16 x 01	DY 2531-1601-1 G
WESTERNBLOT	Anti-HSV-1 / HSV-2 gG-2 EUROLINE-WB (IgM) Herpes simplex virus 1 (HSV-1) plus HSV-2 type-specific glycoprotein G2	Westernblot	whole antigen, SDS extract of HSV-1 plus purified gG2		IgM	16 x 01	DY 2531-1601-1 M
ChLIA	IDS HSV-1 IgG	antigenic coated magnetic particles	gG1 antigen	quantitative		100 x 01	IS-ID5601¹
ChLIA	IDS HSV-2 IgG	antigenic coated magnetic particles	gG2 antigen	quantitative		100 x 01	IS-ID5602¹
ChLIA	IDS HSV 1/2 IgG Control Set	3 x 1.5 ml Control 1/2	human serum			2 concentrations	IS-ID5630¹
ChLIA	IDS HSV 1/2 IgM	antigenic coated magnetic particles	gG1 and gG2 antigens	quantitative		100 x 01	IS-ID5701¹
ChLIA	IDS HSV 1/2 IgM Control Set	3 x 1.5 ml Control 1/2	human serum			2 concentrations	IS-ID5730¹
ChLIA	Anti-Herpes simplex virus 1 ChLIA (IgG)	Antigen-coated magnetic particles	recombinant gG1	quantitative	IgG	100 x 1	LI 2531-10010 G
ChLIA	Anti-Herpes simplex virus 2 ChLIA (IgG)	Antigen-coated magnetic particles	rekombinant gG2	quantitative	IgG	100 x 1	LI 2532-10010 G
ChLIA	Control set Anti-HSV 1 ChLIA (IgG)	2 x 0.5 ml control 1/2			IgG	02 x 02	LR 2531-20210 G
ChLIA	Control set Anti-HSV 2 ChLIA (IgG)	2 x 0.5 ml control 1/2			IgG	02 x 02	LR 2532-20210 G
IIFT	Varicella zoster virus (VZV)	infected cells	EU 168		IgG IgM IgG IgM	10 x 05 10 x 05 10 x 10 10 x 10	FI 2650-1005 G FI 2650-1005 M FI 2650-1010 G FI 2650-1010 M
ELISA	Anti-VZV ELISA (IgA) Varicella zoster virus	antigen-coated microplate wells	native antigens from VZV	semi-quantitative	IgA	96 x 01	EI 2650-9601 A
ELISA	Anti-VZV ELISA (IgG) Varicella zoster virus	antigen-coated microplate wells	native antigens from VZV	10/100/500/5000 IU/l	IgG	96 x 01	EI 2650-9601 G
ELISA	Anti-VZV ELISA (IgM) Varicella zoster virus	antigen-coated microplate wells	native antigens from VZV	semi-quantitative	IgM	96 x 01	EI 2650-9601 M
ELISA	Avidity: Anti-VZV ELISA (IgG) Varicella zoster virus avidity determination	antigen-coated microplate wells	native antigens from VZV	10/100/500/5000 IU/l	IgG	96 x 01	EI 2650-9601-1 G
ELISA	Anti-VZV ELISA 2.0 (IgG) Varicella zoster virus	antigen-coated microplate wells	native antigens from VZV		IgG	96 x 01	EI 2650-9601-2 G
ELISA	Anti-VZV Glycoprotein ELISA (IgM) Varicella zoster virus	antigen-coated microplate wells	native glycoproteins from VZV	semi-quantitative	IgM	96 x 01	EI 2650-9601-2 M
ChLIA	IDS VZV IgG	antigenic coated magnetic particles	VZV virus antigen	quantitative		50 x 01	IS-ID5903¹
ChLIA	IDS MMV IgG Control Set	3 x 1.5 ml Control 1/2	human serum			2 concentrations	IS-ID5930¹
ChLIA	IDS VZV IgM	antigenic coated magnetic particles	VZV virus antigen	quantitative		50 x 01	IS-ID6003¹
ChLIA	IDS MMV IgM Control Set	3 x 1.5 ml Control 1/2	human serum			2 concentrations	IS-ID6030¹
IIFT	Toxoplasma gondii	protozoan smear	Toxoplasma gondii		IgG IgM IgG IgM	10 x 05 10 x 05 10 x 10 10 x 10	FI 2410-1005 G FI 2410-1005 M FI 2410-1010 G FI 2410-1010 M
ELISA	Anti-Toxoplasma gondii ELISA (IgA)	antigen-coated microplate wells	native antigens of Toxoplasma gondii	semi-quantitative	IgA	96 x 01	EI 2410-9601 A
ELISA	Anti-Toxoplasma gondii ELISA (IgM)	antigen-coated microplate wells	native antigens of Toxoplasma gondii	semi-quantitative	IgM	96 x 01	EI 2410-9601 M
ELISA	Avidity: Anti-Toxoplasma gondii ELISA (IgG) avidity determination	antigen-coated microplate wells	native antigens of Toxoplasma gondii	1/10/200 IU/ml	IgG	96 x 01	EI 2410-9601-1 G
ELISA	Anti-Toxoplasma gondii ELISA 2.0 (IgG)	antigen-coated microplate wells	native antigens of Toxoplasma gondii		IgG	96 x 01	EI 2410-9601-2 G
ChLIA	IDS TOXO IgG	antigenic coated magnetic particles	Toxoplasma gondii antigens	quantitative		100 x 01	IS-ID5001¹
ChLIA	IDS TOXO IgM	Anti-IgM-coated magnetic particles	Conjugate: Toxoplasma gondii antigens	quantitative		100 x 01	IS-ID5002¹
ChLIA	IDS TOXO Control Set	3 x 1.5 ml Control 1/2	human serum			2 concentrations	IS-ID5030¹
ChLIA	IDS TOXO IgG Avidity	antigenic coated magnetic particles	Toxoplasma gondii antigens	semi-quantitative		50 x 01	IS-ID5101¹
ChLIA	IDS TOXO Avidity Control Set	3 x 1.0 ml Control 1/2	human serum			2 concentrations	IS-ID5130¹
PCR	EURORealTime Toxoplasma gondii					01 x 100 01 x 25	MP 2410-0100 MP 2410-0125
ELISA	Anti-Parvovirus B19 ELISA (IgG)	antigen-coated microplate wells	recombinant viral structural protein expressed in eukaryotic cells	1/5/25/100 IU/ml	IgG	96 x 01	EI 2580-9601 G
ELISA	Anti-Parvovirus B19 ELISA (IgM)	antigen-coated microplate wells	recombinant viral structural protein expressed in eukaryotic cells	semi-quantitative	IgM	96 x 01	EI 2580-9601 M
ChLIA	IDS Parvovirus B19 IgG	antigenic coated magnetic particles	Structural proteins of Parvovirus B19	semi-quantitative		50 x 01	IS-ID6301¹
ChLIA	IDS Parvovirus B19 IgM	Anti-IgM-coated magnetic particles	Conjugate: structural proteins of Parvovirus B19	quantitative		50 x 01	IS-ID6302¹
ChLIA	IDS Parvovirus B19 Control Set	3 x 1.5 ml Control 1/2	human serum			2 concentrations	IS-ID6330¹
ELISA	Anti-Chlamydia trachomatis Advanced ELISA (IgA)			semi-quantitative	IgA	96 x 01	EI 2191-9601-1 A
ELISA	Anti-Chlamydia trachomatis Advanced ELISA (IgG)			quantitative	IgG	96 x 01	EI 2191-9601-1 G
IIFT	Treponema pallidum (FTA-ABS)	bacterial smear verification BIOCHIP (2 BIOCHIPs per field)	T. pallidum		IgG IgM IgG IgM	10 x 05 10 x 05 10 x 10 10 x 10	FI 2111-1005 G FI 2111-1005 M FI 2111-1010 G FI 2111-1010 M
IIFT	Treponema pallidum (FTA-ABS)	bacterial smears verification BIOCHIP (3 BIOCHIPs per field)	T. pallidum T. phagedenis		IgG IgM IgG IgM	10 x 05 10 x 05 10 x 10 10 x 10	FI 2112-1005 G FI 2112-1005 M FI 2112-1010 G FI 2112-1010 M
IIFT	Anti-Chlamydia MIF Chlamydia trachomatis Chlamydia pneumoniae Chlamydia psittaci	4 BIOCHIPs per field: elementary bodies and non-infected cells	EU 40 EU 40 EU 40		IgA EB IgG EB IgM EB IgA EB IgG EB IgM EB	10 x 05 10 x 05 10 x 05 10 x 10 10 x 10 10 x 10	FI 2191-1005-3 A FI 2191-1005-3 G FI 2191-1005-3 M FI 2191-1010-3 A FI 2191-1010-3 G FI 2191-1010-3 M
IIFT	Chlamydia trachomatis	elementary bodies (MIF) non-infected cells (2 BIOCHIPs per field)	EU 40 EU 40		IgA EB IgG EB IgM EB	10 x 05 10 x 05 10 x 05	FI 2191-1005-80 A FI 2191-1005-80 G FI 2191-1005-80 M
IIFT	Anti-Chlamydia MIF EUROPattern Chlamydia trachomatis Chlamydia pneumoniae Chlamydia psittaci	4 BIOCHIPs per field: elementary bodies and non-infected cells	EU 40 EU 40 EU 40		IgA EB IgG EB IgM EB IgA EB IgG EB IgM EB	10 x 05 10 x 05 10 x 05 10 x 10 10 x 10 10 x 10	FR 2191-1005-3 A FR 2191-1005-3 G FR 2191-1005-3 M FR 2191-1010-3 A FR 2191-1010-3 G FR 2191-1010-3 M
ELISA	Anti-Treponema pallidum ELISA (IgG)	antigen-coated microplate wells	recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA)	2/20/200 RU/ml	IgG	96 x 01	EI 2111-9601 G
ELISA	Anti-Treponema pallidum ELISA (IgM)	antigen-coated microplate wells	recombinant antigens 15 kDa, 17 kDa, 47 kDa, 42 kDa (TmpA)	semi-quantitative	IgM	96 x 01	EI 2111-9601 M
ELISA	Anti-Treponema pallidum ELISA 2.0 (IgGM)			200/50/20/2 RU/ml	IgGM	96 x 01	EI 2111-9601-2 O
ELISA	Anti-Chlamydia trachomatis ELISA (IgA)	antigen-coated microplate wells	native MOMP antigen from C. trachomatis	semi-quantitative	IgA	96 x 01	EI 2191-9601 A
ELISA	Anti-Chlamydia trachomatis ELISA (IgG)	antigen-coated microplate wells	native MOMP antigen from C. trachomatis	2/20/200 RU/ml	IgG	96 x 01	EI 2191-9601 G
ELISA	Anti-Chlamydia trachomatis ELISA (IgM)	antigen-coated microplate wells	native MOMP antigen from C. trachomatis	semi-quantitative	IgM	96 x 01	EI 2191-9601 M
EUROLINE	positive control serum: IgG, human, 50x concentrated for Treponema pallidum				IgG	05 x 07	CL 2111-0507 G
EUROLINE	positive control serum: IgM, human, 50x concentrated for Treponema pallidum				IgM	05 x 07	CL 2111-0507 M
EUROLINE	EUROLINE Anti-Treponema pallidum (IgG) (TpN15, TpN17, TmpA, TpN47 separately)	EUROLINE			IgG IgG	16 x 01 64 x 01	DN 2111-1601 G DN 2111-6401 G
EUROLINE	EUROLINE Anti-Treponema pallidum (IgM) (TpN15, TpN17, TmpA, TpN47 separately)	EUROLINE			IgM IgM	16 x 01 64 x 01	DN 2111-1601 M DN 2111-6401 M
WESTERNBLOT	antibodies against Treponema pallidum IgG positive control				IgG	50 x 05	CW 2111-5005 G
WESTERNBLOT	antibodies against Treponema pallidum IgM positive control				IgM	50 x 05	CW 2111-5005 M
WESTERNBLOT	Anti-Treponema pallidum WESTERNBLOT (IgG)	Westernblot	15 kDa, 17 kDa, 45 kDa (tmpA), 47 kDa		IgG IgG	16 x 01 24 x 01	DY 2111-1601 G DY 2111-2401 G
WESTERNBLOT	Anti-Treponema pallidum WESTERNBLOT (IgM)	Westernblot	15 kDa, 17 kDa, 45 kDa (tmpA), 47 kDa		IgM IgM	16 x 01 24 x 01	DY 2111-1601 M DY 2111-2401 M
ELISA	Avidity: Anti-Rubella Virus ELISA (IgG) avidity determination	antigen-coated microplate wells	native antigens, strain "HPV-77"	1/10/50/200 IU/ml	IgG	96 x 01	EI 2590-9601-1 G
ELISA	Anti-Rubella Virus Glycoprotein ELISA (IgM)	antigen-coated microplate wells	native glycoproteins, strain "HPV-77"	semi-quantitative	IgM	96 x 01	EI 2590-9601-2 M
ELISA	Anti-Rubella Virus ELISA 2.0 (IgG)	antigen-coated microplate wells	Recombinant Rubella virus antigens		IgG	96 x 01	EI 2590-9601-3 G
ChLIA	IDS Rubella IgG	antigenic coated magnetic particles	Rubella antigen	quantitative		100 x 01	IS-ID5201¹
ChLIA	IDS Rubella IgM	Anti-IgM-coated magnetic particles	Conjugate: Rubella antigen	quantitative		100 x 01	IS-ID5202¹
ChLIA	IDS Rubella Control Set	3 x 1.5 ml Control 1/2	human serum			2 concentrations	IS-ID5230¹
ChLIA	IDS Rubella IgG Avidity	antigenic coated magnetic particles	Rubella antigen	quantitative		50 x 01	IS-ID5301¹
ChLIA	IDS Rubella Avidity Control Set	3 x 1.0 ml Control 1/2	human serum			2 concentrations	IS-ID5330¹
* For research use only, not for in vitro diagnostic use in the sense of EU directive 98/79/EC. ¹ Product manufactured by third party. Please contact your local Euroimmun representative for more information.